Effect Evaluation of <italic style="font-style: italic">Strychnos nux-vomica</italic> L. with Integrative Methods for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patients: A Self-Controlled Clinical Trial

Tie-ying DAI; Chu-chu CHEN; Li-li HONG; Hang-ping Ge; Jun PEI; Wen-qi LYU; Xue YANG; Jian-ping SHEN; Zhi-ping HU

doi:10.1007/s11655-020-3196-2

Your Location：

Home >

Browse articles >

Effect Evaluation of Strychnos nux-vomica L. with Integrative Methods for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patients: A Self-Controlled Clinical Trial

Clinical Experience | Updated：2021-08-16

- Effect Evaluation of Strychnos nux-vomica L. with Integrative Methods for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patients: A Self-Controlled Clinical Trial
- Chinese Journal of Integrative Medicine Vol. 27, Issue 2, Pages: 131-136(2021)
- Affiliations：
  
  Department of Hematology, the First Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou(310006), China
- Author bio：
  
  Correspondence to: Prof. HU Zhi-ping, E-mail: hzpzy@163.com
- Funds：
- DOI：10.1007/s11655-020-3196-2
  CLC：
- Published：01 February 2021，
  
  Published Online：16 May 2020，
  
  Accepted：22 December 2019
Scan for full text
Tie-ying DAI, Chu-chu CHEN, Li-li HONG, et al. Effect Evaluation of Strychnos nux-vomica L. with Integrative Methods for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patients: A Self-Controlled Clinical Trial. [J]. Chinese Journal of Integrative Medicine 27(2):131-136(2021)
DOI：

Tie-ying DAI, Chu-chu CHEN, Li-li HONG, et al. Effect Evaluation of Strychnos nux-vomica L. with Integrative Methods for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patients: A Self-Controlled Clinical Trial. [J]. Chinese Journal of Integrative Medicine 27(2):131-136(2021) DOI： 10.1007/s11655-020-3196-2.

摘要

Abstract

Objective:

To explore the clinical effect and adverse reactions of

Strychnos nux-vomica

in bortezomib-induced peripheral neuropathy (BIPN) of patients with multiple myeloma (MM).

Methods:

A total of 19 MM patients with BIPN were enrolled and Nux Vomica Capsule (NVC

0.4 g

thrice daily) were orally administrated for 30 days. Comparative analysis on parameters between pre- and post-therapy

including peripheral neuropathy (PN) grade

neurotoxicity score

Chinese medicine (CM) syndrome score

total neuropathy score (TNS)

coagulation function

and serum nerve growth factor (NGF) levels were conducted. The adverse events were monitored.

Results:

In BIPN of MM patients who received NVC

PN grade was lowered

neurotoxicity score was obviously decreased (

≤0.01)

and both CM syndrome score and TNS were remarkably decreased (

0.01). After the therapy

activated partial thromboplastin time was prolonged (

0.01) and fibrinogen was declined (

0.05)

showing improvement in the hypercoagulable state of patients. No significant difference of NGF recovery degrees was detected between pre- and post-therapy (

0.05). No evident adverse reactions were observed during the course of treatment.

Conclusion:

Strychnos nux-vomica L. has significantly effect with a good safety in treatment of BIPN in MM patients.

关键词

Keywords

bortezomib-induced peripheral neuropathygrilled nux vomicatotal neuropathy scoreChinese medicine syndrome scorenerve growth factor

references

Anderson KC, Alsina M, Bensinger W, Biermann JS,Chanan-Khan A, Cohen AD, et al. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Cancer Netw 2009;7:908-942.

Curran MP, McKeage K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs 2009;69:859-888.

Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112:1593-1599.

Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 2010;36 Suppl 2:S24-S32.

Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010;116:4745-4753.

Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AL, Lopez de la Guia A, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 2012;120:2581-2588.

Zhang Y, Wu W, Gu W. A clinical study of subcutaneous bortezomib in the treatment of multiple myeloma. Chin J Modern Drug Appl (Chin) 2016;6:161-162.

Arnulf B, Pylypenko H, Grosicki S, Karamanesht L, Leleu X, van de Velde H, et al. Updated survival analysis of a randomized phase Ⅲ study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012;97:1925-1928.

Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M,Ludwing H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010;11:1086-1095.

Bao T, Goloubeva O, Pelser C, Porter NP, Primrose J,Hester LH, et al. A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Integr Cancer Ther 2014;13:396-404.

National Pharmacopoeia Committee. Pharmacopoeia of People's Republic of China. Part 1. Beijing: Chemical Industry Press; 2005.

Dong G, Hou Q, Pei J. An experimental study of grilled nux vomica in the treatment of rabbit model of myasthenia gravis. Chin J Tradit Med Sci Technol (Chin) 2005;12:3651.

Zhang Z, ed. Diagnostic and therapeutic effect criteria for hematological diseases. 3rd ed. Beijing: Science Press;2007:232-233.

Multiple Myeloma Specialized Committee. Chinese expert consensus on diagnosis and treatment of multiple myeloma peripheral neuropathy 2015. Chin J Intern Med (Chin)2015:54;821-824.

Qiu CL, Jin XL. Toxic reaction and premution of Strychnos nux-vomica L. in treating myasthenia gravis. Chin J Modern Appl Pharm (Chin) 1998;2:35.

Zhou J, Bian H, Ma C, Cai B, Wang T. Study on the antiplatelet aggregation and antithrombosis effects of strychnine and brucine N-oxide. Jiangsu J Tradit Chin Med(Chin) 1998;4(4):41-43.

Wang Y, Zhang LQ. Changlin's experience in the treatment of flaccidity syndrome. J Tradit Chin Med (Chin)2004;51:17-19.

Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. Version 4. Evanston, IL: Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University; 1997.

Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman D, Hunt TL, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003;13:741-748.

Chen XJ, Zhang BL. Internal medicine of traditional Chinese medicine.Beijing: Science Press; 2007:157-161.

Pang G, Yan Y, Zhu P. First draft of TCM diagnosis and treatment of diabetic peripheral neuropathy. China J Tradit Chin Med Pharm (Chin) 2010;25:260-264.

Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C,et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007;12:210-215.

Adverse Drug Reaction Evaluation Criteria. World Health Orgaization; 1979.

Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007;204:317-325.

Gilmore TD, Garbati MR. Inhibition of NF-κB signaling as a strategy in disease therapy. Curr Top Microbiol Immunol 2011;349:245-263.

Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase Ⅲ APEX study. J Clin Oncol 2008;26:4784-4790.

Corthals SL, Kuiper R, Johnson DC, Sonneveld P, Hajek R, van der Holt B, et al. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica 2011;96:1728-1732.

Wang X, Li P. Pharmacological effects of nux vomica. Clin J Tradit Chin Med (Chin) 2008;20:198-200.

Qiu T, Chen M. Clinical observation of Nux Vomica Capsules in the treatment of 31 cases of myasthenia gravis. Chin J Tradit Chin Med Sci Technol (Chin) 2008;15:219-220.

Chen Q, Liu Y, Cui M, Han D, Bai Y, Su M, et al. Advances in study of in vivo processes and pharmacodynamic mechanism of nux vomica. Rheumat Arthrit (Chin) 2015;10:57-62.

Gao Y, Ye B, Zhou Y. Long-term therapeutic effect of grilled Nux Vomica Capsule plus autologous peripheral stem cell transplantation in the treatment of refractory myasthenia gravis. Modern J Integr Tradit Chin West Med (Chin)2010;19:2341-2350.

Qian M, Hou Q, Pei J. An experimental study of grilled nux vomica plus hyperbaric oxygen treatment for rabbit spinal cord injury. Chin J Tradit Chin Med Sci Technol (Chin)2009;16:182-183.

Zhang J, Xiao L, Dai T. Exploration of the analgesic effect of brucine and its mechanism. Chin J Tradit Chin Med Sci Technol (Chin) 2009;16:374-375.

Cao D, Liu Z, Yue L. Observation of the therapeutic effect of self-made Logan Tongbi Capsule in 60 cases of sciatica.Heilongjiang J Tradit Chin Med (Chin) 2007;50:17-18.

Xu X, Zhang X. A clinical study of Maomei Decoction plus vitamin B12 in the treatment of velcade-caused multiple myeloma peripheral neuropathy. Chin J Tradit Chin Med Sci Technol (Chin) 2012;19:13-14.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Effects of Qingre Huoxue Jiedu Formula on Nerve Growth Factor-Induced Psoriasis

Guizhi Decoction (桂枝汤) Inhibits Cholinergic Transdifferentiation by Regulating Imbalance of NGF and LIF in Salt-Sensitive Hypertensive Heart Failure Rats

Related Author

No data

Related Institution

Dermatology Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Dermatology Department, Dongfang Hospital,Beijing University of Chinese Medicine

Laboratory of Molecular Biology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences

First Clinical Medical College, Shandong University of Traditional Chinese Medicine

Department of Cardiovascular, Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Effect Evaluation of Strychnos nux-vomica L. with Integrative Methods for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patients: A Self-Controlled Clinical Trial

DOI：10.1007/s11655-020-3196-2

摘要

Abstract

关键词

Keywords

references